UMN Pharma’s Avian Flu Vaccine Trial Confirms Efficacy and Safety
This article was originally published in PharmAsia News
Executive Summary
Akita based UMN Pharma announced that a clinical trial conducted in 2008 on 125 healthy males aged 20 to 40 in Tokyo confirmed efficacy and safety of UMN-0501, a H5N1 type avian flu vaccine. The company will release the details of the trial result at the World Health Organization's avian flu conference in February. UMN Pharma also plans to start a new trial for the flu vaccine with added effective ingredients within the year. UMN-0501 has been designated an orphan drug in Japan and the company receives assistance to cover development expenses. (Click here for more - Japanese language